Pure Global

A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression - Trial NCT06259526

Access comprehensive clinical trial information for NCT06259526 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Recruiting. The study focuses on Depression. Target enrollment is 260 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06259526
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06259526
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Study Focus

Depression

Placebo group

Interventional

drug

Sponsor & Location

Tasly Pharmaceutical Group Co., Ltd

Beijing,Peking,Chongqing,Chongqing,Guangzhou,Baoding,Shijiazhuang,Daqing,Wuxi,Zhenjiang,Nanchang,Siping,Jinan,Tianjin,Ürümqi,Kunming,Huzhou, China

Timeline & Enrollment

Phase 2

Dec 26, 2023

Apr 26, 2025

260 participants

Primary Outcome

The change in MADRS total score from baseline

Summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients
 With Moderate to Severe Depression

ICD-10 Classifications

Depressive episode
Other depressive episodes
Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Post-schizophrenic depression

Data Source

ClinicalTrials.gov

NCT06259526

Non-Device Trial